4.88 USD
-0.19 (-3.75%)
At close: Jan 30, 2026
4.99 USD
+0.11 (+2.25%)
After Hours: 1/30/2026, 8:19:49 PM
SRTA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. While SRTA has a great health rating, there are worries on its profitability. SRTA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year SRTA has reported negative net income.
- In the past year SRTA has reported a negative cash flow from operations.
- In the past 5 years SRTA always reported negative net income.
- SRTA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- SRTA has a Return On Assets of 12.05%. This is amongst the best in the industry. SRTA outperforms 97.09% of its industry peers.
- Looking at the Return On Equity, with a value of 14.27%, SRTA belongs to the top of the industry, outperforming 80.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.05% | ||
| ROE | 14.27% | ||
| ROIC | N/A |
ROA(3y)-12.68%
ROA(5y)-33.09%
ROE(3y)-15.39%
ROE(5y)-48.99%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 17.65%, SRTA belongs to the best of the industry, outperforming 99.03% of the companies in the same industry.
- Looking at the Gross Margin, with a value of 23.78%, SRTA is in line with its industry, outperforming 49.51% of the companies in the same industry.
- SRTA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 17.65% | ||
| GM | 23.78% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.59%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- SRTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for SRTA has been increased compared to 1 year ago.
- SRTA has more shares outstanding than it did 5 years ago.
- SRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- SRTA has an Altman-Z score of 5.05. This indicates that SRTA is financially healthy and has little risk of bankruptcy at the moment.
- SRTA's Altman-Z score of 5.05 is amongst the best of the industry. SRTA outperforms 85.44% of its industry peers.
- SRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.05 |
ROIC/WACCN/A
WACC8.9%
2.3 Liquidity
- A Current Ratio of 4.39 indicates that SRTA has no problem at all paying its short term obligations.
- SRTA's Current ratio of 4.39 is amongst the best of the industry. SRTA outperforms 92.23% of its industry peers.
- A Quick Ratio of 4.39 indicates that SRTA has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 4.39, SRTA belongs to the top of the industry, outperforming 92.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.39 | ||
| Quick Ratio | 4.39 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 60.87% over the past year.
- The Revenue has decreased by -5.40% in the past year.
- SRTA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 70.13% yearly.
EPS 1Y (TTM)60.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y70.13%
Revenue growth 5YN/A
Sales Q2Q%-34.16%
3.2 Future
- Based on estimates for the next years, SRTA will show a very strong growth in Earnings Per Share. The EPS will grow by 24.23% on average per year.
- Based on estimates for the next years, SRTA will show a small growth in Revenue. The Revenue will grow by 7.57% on average per year.
EPS Next Y58.65%
EPS Next 2Y35.96%
EPS Next 3Y24.23%
EPS Next 5YN/A
Revenue Next Year-12.66%
Revenue Next 2Y4.34%
Revenue Next 3Y7.57%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- SRTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year SRTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as SRTA's earnings are expected to grow with 24.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.96%
EPS Next 3Y24.23%
5. Dividend
5.1 Amount
- SRTA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
STRATA CRITICAL MEDICAL INC / SRTA FAQ
What is the ChartMill fundamental rating of STRATA CRITICAL MEDICAL INC (SRTA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to SRTA.
Can you provide the valuation status for STRATA CRITICAL MEDICAL INC?
ChartMill assigns a valuation rating of 1 / 10 to STRATA CRITICAL MEDICAL INC (SRTA). This can be considered as Overvalued.
What is the profitability of SRTA stock?
STRATA CRITICAL MEDICAL INC (SRTA) has a profitability rating of 3 / 10.
What is the financial health of STRATA CRITICAL MEDICAL INC (SRTA) stock?
The financial health rating of STRATA CRITICAL MEDICAL INC (SRTA) is 8 / 10.
What is the expected EPS growth for STRATA CRITICAL MEDICAL INC (SRTA) stock?
The Earnings per Share (EPS) of STRATA CRITICAL MEDICAL INC (SRTA) is expected to grow by 58.65% in the next year.